Camptothecin Derivatives Antitumor Database

Cancer is a global health problem and one of the leading causes of human death. According to the data released by the International Agency for Research on Cancer (IARC) in 2022, there were 19.3 million new cancer cases and nearly 10 million cancer deaths worldwide in 2020. At the same time, with rising morbidity and mortality, cancer has become the leading cause of death and a major public health problem for the Chinese population. China ranked first in the world in the number of new cancer cases and deaths in 2020. Camptothecin (CPT) , which has extensive antitumor activity, is a natural pentacyclic monoterpene alkaloid isolated from Camptotheca acuminata by Wall and Wani in 1966. In the 1970s, CPT was clinically approved to treat stomach cancer, bladder cancer, and certain types of leukemia. Camptothecin, as a natural drug candidate parent nucleus, has developed so far, and a large number of derivatives have been derived. The CDAD database integrates the latest laboratory data on the inhibition of cancer cells by camptothecin derivatives, as well as the anti-cancer data of camptothecin derivatives in the previously published literature. Each entry contains detailed information about the camptothecin derivatives, such as SMILE, molecular weight, IUPAC designation, median inhibition concentration (IC50), duration of action, target and related literature and patents, etc. This data will contribute to the further development of camptothecin derivatives and promote the anticancer research of camptothecin derivatives.